DEA removes exemptions for inactive butalbital products
Oct 11, 2026 edition · GC-2026-0259 · Published 2026-10-11 · Version 3 · Final
DEA's October 9 determination removes exemption status for listed inactive butalbital product NDCs from November 9. It expressly leaves exempt products with active NDCs unaffected and describes a table cleanup of products no longer marketed, rather than a universal change for every butalbital formulation.
What happened
DEA's final determination published October 9 revokes exempt-prescription status for listed butalbital products whose NDCs are inactive because they are unavailable or the original applicant no longer exists. The determination takes effect November 9, 2026 and removes the identified entries from the exemption table. DEA expressly says the action does not affect exempt products with active NDCs. Product identity and table status therefore matter before translating this action into dispensing or inventory changes.
The source identifies butalbital as a Schedule III barbiturate and explains the historical exemption for certain combinations intended to reduce abuse potential. Of 189 listed products, DEA identified 160 inactive NDCs and confirmed with FDA that they were no longer marketed before proposing removal. It describes this action as having no practical effect on those unavailable products. That rationale should remain distinct from a conclusion that all currently marketed combinations lose their exemption, or that a new application or product inherits exemption solely because it contains the same ingredients.
Scope and timing
- Authority status
- Final
- Applicability
- Directly applicable
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal
- Recorded date
- 2026-11-09
- Date type
- effective
Why it matters
Active exempt NDCs are unaffected. DEA describes the removed products as no longer marketed; this is not a blanket scheduling change for all butalbital combination products.
Recommended action
Pharmacy compliance should reconcile any legacy product master entries against the exact removed NDCs and preserve the distinction between inactive and active exemptions.
Sources
- DEA inactive butalbital product determinationOfficial · DEA · 2026-10-09 · Source review 2026-10-11
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Compliance Sweep report →